Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

Fibrate treatment for primary biliary cirrhosis

Cuperus, Frans J.C., Halilbasic, Emina, Trauner, Michael · 2014 · Current Opinion in Gastroenterology

Abstract

Purpose of review Primary biliary cirrhosis (PBC) can lead to end-stage liver disease and death. Ursodeoxycholic acid (UDCA) treatment can normalize serum liver enzymes in PBC, and such UDCA-responsive patients have a similar life expectancy as age and sex-matched controls. Nearly up to 50% of the patients with PBC, depending on sex and age at diagnosis, show an incomplete biochemical response to UDCA and require additional/alternative treatment. The purpose of this review is to critically evaluate the molecular mechanisms and clinical benefit of fibrate treatment in these patients. Recent findings Fibrates have anticholestatic, anti-inflammatory, and antifibrotic effects in animal and in-vitro studies. The mechanisms that underlie these effects are complementary, and largely mediated through activation of peroxisome proliferator activated receptors. Fibrate treatment ameliorated liver biochemical tests in UDCA unresponsive patients, either as mono-therapy or in combination with UDCA. These results, however, were obtained in case series and small pilot studies. The results of phase III studies, such as the Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (BEZURSO) trial, are currently awaited. Summary A considerable body of observational evidence supports the safety and efficacy of fibrate treatment in PBC patients with an incomplete response to UDCA. These results encourage the evaluation of its effects on liver-related morbidity and mortalit…

Overview

Integrity signals

Registry

Crossref · 10.1097/mog.0000000000000056

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 91 references

Research works printed but not linked: 7

  1. Rudic, 2012, Cochrane Database Syst Rev, 12, CD000551
  2. Mason, 2010, Hepatology, 52, 357A
  3. Hirschfield, 2011, Hepatology, 54, 429A
  4. Marra, 2005, World J Gastroenterol, 11, 4931
  5. Kanda, 2003, astroenterol, 38, 573
  6. Yano, 2002, astroenterol, 97, 1075
  7. Miyaguchi, 2000, epatogastroenterology, 47, 1518

Cited by

See all 36

Metadata

Authors
Cuperus, F. J. C., Halilbasic, E., & Trauner, M.
Affiliations
Medical University of Vienna (AT)
Corresponding author
Trauner, Michael
Venue
Current Opinion in Gastroenterology
Published
2014-05
Volume
30
Issue
3
Pages
279-286
ISSN
0267-1379 (ISSN-L)
OpenAlex
W2171885360
Cited by
36
References
91
Citations by year
2024: 1 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 3 · 2019: 5 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 8
FWCI
0.74
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords
primary biliary cirrhosis, fibrate therapy, bezafibrate, ursodeoxycholic acid, peroxisome proliferator-activated receptors, antifibrotic effect, anti-inflammatory activity, combination therapy, liver enzymes
MeSH terms
Anti-Inflammatory Agents, Non-Steroidal, Hypolipidemic Agents, Drug Therapy, Combination, Humans, Liver Cirrhosis, Biliary, Ursodeoxycholic Acid, Treatment Outcome, Treatment Failure, Fibric Acids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibrate treatment for primary biliary cirrhosis. https://app.cochat.ai/papers/10.1097/mog.0000000000000056
The paper
Cuperus, F. J. C., Halilbasic, E., & Trauner, M. (2014). Fibrate treatment for primary biliary cirrhosis. Current Opinion in Gastroenterology. https://doi.org/10.1097/mog.0000000000000056

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.